 |
BioWorld-International-2003-07-16
SARS Virus Has Good Targets For Drug Makers, Study Shows
Medivir, Boehringer Ingelheim Enter Potential EUR122M Alliance
As he put it himself, Medivir AB CEO Lars Adlersson had "two reasons to celebrate" Tuesday. The drug discovery company he leads had just signed its largest deal ever, a pact potentially worth €122 million with Boehringer Ingelheim GmbH to develop its candidate HIV drug MIV-310. It was also his 39th birthday. (BioWorld International)